Central nervous system toxicity associated with weekly low‐dose methotrexate treatment

Richard Wernick, David Smith

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Central nervous system (CNS) toxicity from low‐dose methotrexate (MTX) has been reported rarely, and reported symptoms consist primarily of dizziness and headache. We reviewed the records of 25 consecutive patients treated with low‐dose MTX, and found 5 who had spontaneously reported unpleasant cranial sensations, mood alteration, or memory impairment. Rechallenge with MTX on 5 occasions in 3 patients led to recurrent CNS symptoms in all cases. CNS toxicity was the sole reason for discontinuation of MTX in 2 patients. These 5 patients differed from the 20 without CNS toxicity in age (mean 68 versus 50) and baseline serum creatinine level (1.3 mg/dl versus 0.9 mg/dl), but not in weekly dosage of MTX (12 mg versus 16 mg). These results suggest that CNS toxicity is more common than previously reported, particularly in older patients with mild renal insufficiency.

Original languageEnglish (US)
Pages (from-to)770-775
Number of pages6
JournalArthritis Care and Research
Volume32
Issue number6
DOIs
StatePublished - 1989

Fingerprint

Methotrexate
Central Nervous System
Therapeutics
Dizziness
Renal Insufficiency
Headache
Creatinine
Serum

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Central nervous system toxicity associated with weekly low‐dose methotrexate treatment. / Wernick, Richard; Smith, David.

In: Arthritis Care and Research, Vol. 32, No. 6, 1989, p. 770-775.

Research output: Contribution to journalArticle

@article{e24d86fb397e423db72be0cfb38168ea,
title = "Central nervous system toxicity associated with weekly low‐dose methotrexate treatment",
abstract = "Central nervous system (CNS) toxicity from low‐dose methotrexate (MTX) has been reported rarely, and reported symptoms consist primarily of dizziness and headache. We reviewed the records of 25 consecutive patients treated with low‐dose MTX, and found 5 who had spontaneously reported unpleasant cranial sensations, mood alteration, or memory impairment. Rechallenge with MTX on 5 occasions in 3 patients led to recurrent CNS symptoms in all cases. CNS toxicity was the sole reason for discontinuation of MTX in 2 patients. These 5 patients differed from the 20 without CNS toxicity in age (mean 68 versus 50) and baseline serum creatinine level (1.3 mg/dl versus 0.9 mg/dl), but not in weekly dosage of MTX (12 mg versus 16 mg). These results suggest that CNS toxicity is more common than previously reported, particularly in older patients with mild renal insufficiency.",
author = "Richard Wernick and David Smith",
year = "1989",
doi = "10.1002/anr.1780320616",
language = "English (US)",
volume = "32",
pages = "770--775",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Central nervous system toxicity associated with weekly low‐dose methotrexate treatment

AU - Wernick, Richard

AU - Smith, David

PY - 1989

Y1 - 1989

N2 - Central nervous system (CNS) toxicity from low‐dose methotrexate (MTX) has been reported rarely, and reported symptoms consist primarily of dizziness and headache. We reviewed the records of 25 consecutive patients treated with low‐dose MTX, and found 5 who had spontaneously reported unpleasant cranial sensations, mood alteration, or memory impairment. Rechallenge with MTX on 5 occasions in 3 patients led to recurrent CNS symptoms in all cases. CNS toxicity was the sole reason for discontinuation of MTX in 2 patients. These 5 patients differed from the 20 without CNS toxicity in age (mean 68 versus 50) and baseline serum creatinine level (1.3 mg/dl versus 0.9 mg/dl), but not in weekly dosage of MTX (12 mg versus 16 mg). These results suggest that CNS toxicity is more common than previously reported, particularly in older patients with mild renal insufficiency.

AB - Central nervous system (CNS) toxicity from low‐dose methotrexate (MTX) has been reported rarely, and reported symptoms consist primarily of dizziness and headache. We reviewed the records of 25 consecutive patients treated with low‐dose MTX, and found 5 who had spontaneously reported unpleasant cranial sensations, mood alteration, or memory impairment. Rechallenge with MTX on 5 occasions in 3 patients led to recurrent CNS symptoms in all cases. CNS toxicity was the sole reason for discontinuation of MTX in 2 patients. These 5 patients differed from the 20 without CNS toxicity in age (mean 68 versus 50) and baseline serum creatinine level (1.3 mg/dl versus 0.9 mg/dl), but not in weekly dosage of MTX (12 mg versus 16 mg). These results suggest that CNS toxicity is more common than previously reported, particularly in older patients with mild renal insufficiency.

UR - http://www.scopus.com/inward/record.url?scp=0024334546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024334546&partnerID=8YFLogxK

U2 - 10.1002/anr.1780320616

DO - 10.1002/anr.1780320616

M3 - Article

VL - 32

SP - 770

EP - 775

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 6

ER -